TY  - GEN
AU  - Altorki,N K
AU  - Keresztes,R S
AU  - Port,J L
AU  - Libby,D M
AU  - Korst,R J
AU  - Flieder,D B
AU  - Ferrara,C A
AU  - Yankelevitz,D F
AU  - Subbaramaiah,K
AU  - Pasmantier,M W
AU  - Dannenberg,A J
TI  - Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer
SN  - 0732-183X
PY  - 2003///0814
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carboplatin
KW  - administration & dosage
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Celecoxib
KW  - Chemotherapy, Adjuvant
KW  - Cyclooxygenase Inhibitors
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Drug Synergism
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Paclitaxel
KW  - Pneumonectomy
KW  - Preoperative Care
KW  - methods
KW  - Pyrazoles
KW  - Sulfonamides
KW  - Survival Analysis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2003.07.127
ER  -